

Table S1 Baseline characteristics of patients in propensity-score matched cohort

Characteristics	Non-PLND (n=190)	PLND (n=190)	P value	Obturator resection (n=118)	ePLND (n=118)	P value
Age (years)	67.84±7.29	67.02±6.69	0.279	69 (64.75–73.25)	67 (62.0–72.25)	0.075
BMI (kg/m ²)	24.23 (22.79–25.92)	24.20 (22.31–26.37)	0.810	24.22 (22.77–25.71)	23.94 (22.31–25.79)	0.396
PSA (ng/mL)	10.26 (7.02–16.63)	11.3 (7.48–17.48)	0.434	16.31 (11.49–30.34)	16.48 (9.3–30.85)	0.448
Clinical T stage			0.001			0.446
T1	45 (23.7)	61 (32.1)		29 (24.6)	21 (17.8)	
T2	139 (73.2)	108 (56.8)		69 (58.5)	77 (65.3)	
T3	5 (2.6)	20 (10.5)		20 (16.9)	20 (16.9)	
T4	1 (0.5)	1 (0.5)		–	–	
ISUP grade			0.003			0.678
ISUP-1	36 (18.9)	63 (33.2)		11 (9.3)	12 (10.2)	
ISUP-2	75 (39.5)	53 (27.9)		23 (19.5)	28 (23.7)	
ISUP-3	48 (25.3)	32 (16.8)		15 (12.7)	18 (15.3)	
ISUP-4	23 (12.1)	31 (16.3)		38 (32.2)	28 (23.7)	
ISUP-5	8 (4.2)	11 (5.8)		31 (26.3)	32 (27.1)	
Risk stratification			0.066			0.753
Low	12 (6.3)	24 (12.6)		4 (3.4)	5 (4.2)	
Intermediate	93 (48.9)	78 (41.1)		20 (16.9)	24 (20.3)	
High	85 (44.7)	88 (46.3)		94 (79.7)	89 (75.4)	

Data are presented as mean ± standard deviation, mean (range) or n (%). PLND, pelvic lymph node dissection; ePLND, extended pelvic lymph node dissection; BMI, body mass index; PSA, prostate-specific antigen; ISUP, International Society of Urological Pathology.